comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Real-World Evidence for GLP-1 Receptor
Description
Is Saxenda (liraglutide) a GLP-1 medication
2 In the full study population, breast cancer was diagnosed in 1.62% (247/15,264) of women with GLP-1 exposure compared with 2.47% (2,381/96,382) of women without exposure, corresponding to an odds ratio (OR) of 0.649 (95% CI, 0.5690.741
A total of 636 patients were randomized into equally sized four study arms
69% of patients achieved more than 10% weight loss compared to 9% on placebo
